Shares of Affymax spiked more than 25% this morning as investors got a chance to show their enthusiasm for the big support FDA experts provided Wednesday afternoon for the biotech’s experimental anemia drug peginesatide. The panelists voted 15 to …
Archive for the ‘Affymax’ Category
Affymax spikes after expert panel backs new anemia drug rival to Amgen
December 8th, 2011 
John Carroll 
Posted in Affymax, Amgen, Anemia drugs, Blog, Companies, Diagnostics, Dr. Steven Nissen, Epogen, Funding, Medical Devices, Medical Supply, Pharmaceuticals, Startups, Takeda, Universities, Videos 
Tags: biotech food social media 
Comments OffAffymax investors bullish on FDA review of Amgen anemia drug rival
December 5th, 2011 John Carroll Facing an expert panel review for peginesatide on Wednesday, FDA staffers gave Affymax ($AFFY) a solid boost in confidence this morning with an agency review that backed the once-monthly anemia treatment as equivalent to Amgen’s ($AMGN) blockbuster tre…
Posted in Affymax, Amgen, Aranesp, Blog, Companies, Diagnostics, Epogen, Funding, Medical Devices, Medical Supply, Pharmaceuticals, Startups, Universities, Videos Tags: biotech food social media Comments OffPotential rival to Amgen’s anemia drug faces big day with FDA advisers
November 18th, 2011 Ryan McBride Affymax ($AFFY) has been part of a “David and Goliath” story for years, with the small biotech developing an anemia drug called peginesatide for kidney dialysis patients that could rival Epogen, from industry giant Amgen ($AMGN), if approved….
Posted in Affymax, Amgen, Anemia drugs, Blog, Companies, Diagnostics, Funding, Medical Devices, Medical Supply, Pharmaceuticals, Startups, Takeda, Universities, Videos Comments Off